Generative AI in drug development
by Giuliana Miglierini Generative AI is perhaps the more advanced form of artificial intelligence available today, as it…
EMA’s pilot scheme for academic and non-profit development of ATMPs
by Giuliana Miglierini Advanced therapy medicinal products (ATMPs) are often developed by academic and non-profit organisations, because of…
Reactions to the proposed ban of PFAS
by Giuliana Miglierini A proposal to ban around 10,000 per- and polyfluoroalkyl substances (PFAS) was submitted in January…
EU’s Industrial Forum, the future of advanced manufacturing technologies
by Giuliana Miglierini The expert group “Industrial Forum” is a multistakeholder body created by the European Commission to…
The debate on the “Do No Significant Harm” principle in R&D
by Giulianna Miglierini The “Do No Significant Harm” (DNSH) principle is a widely diffused approach aimed to guarantee…
Trends for the future of the pharmaceutical manufacturing
By Giuliana Miglierini The technological evolution of pharmaceutical manufacturing towards the full implementation of the Industry 4.0 paradigm…